[go: up one dir, main page]

TN2014000337A1 - Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status - Google Patents

Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status

Info

Publication number
TN2014000337A1
TN2014000337A1 TNP2014000337A TN2014000337A TN2014000337A1 TN 2014000337 A1 TN2014000337 A1 TN 2014000337A1 TN P2014000337 A TNP2014000337 A TN P2014000337A TN 2014000337 A TN2014000337 A TN 2014000337A TN 2014000337 A1 TN2014000337 A1 TN 2014000337A1
Authority
TN
Tunisia
Prior art keywords
rnf43
znrf3
administration
cancer patient
wnt signaling
Prior art date
Application number
TNP2014000337A
Other languages
English (en)
Inventor
Feng Cong
Huaixiang Hao
Hsin-I Hsieh
Xiaomo Jiang
Jun Liu
Nicholas Ng
Original Assignee
Novartis Ag
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47790546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2014000337(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Irm Llc filed Critical Novartis Ag
Publication of TN2014000337A1 publication Critical patent/TN2014000337A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57438Specifically defined cancers of liver, pancreas or kidney
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TNP2014000337A 2012-02-28 2014-08-05 Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status TN2014000337A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261604290P 2012-02-28 2012-02-28
PCT/US2013/027441 WO2013130364A1 (fr) 2012-02-28 2013-02-22 Sélection de patient atteints d'un cancer pour administrer des inhibiteurs de signalisation de la voie wnt au moyen de l'état de mutation rnf43

Publications (1)

Publication Number Publication Date
TN2014000337A1 true TN2014000337A1 (en) 2015-12-21

Family

ID=47790546

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2014000337A TN2014000337A1 (en) 2012-02-28 2014-08-05 Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status

Country Status (19)

Country Link
US (3) US20150125857A1 (fr)
EP (2) EP3693476B1 (fr)
JP (2) JP6397335B2 (fr)
KR (1) KR20140132712A (fr)
CN (1) CN104302782A (fr)
AU (1) AU2013226323B2 (fr)
BR (1) BR112014020233A2 (fr)
CA (1) CA2864306A1 (fr)
CL (1) CL2014002269A1 (fr)
ES (2) ES2797533T3 (fr)
IL (1) IL233920A0 (fr)
MX (1) MX2014010265A (fr)
NZ (1) NZ627864A (fr)
PH (1) PH12014501930A1 (fr)
RU (2) RU2017120287A (fr)
SG (1) SG11201404492VA (fr)
TN (1) TN2014000337A1 (fr)
WO (1) WO2013130364A1 (fr)
ZA (1) ZA201405553B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2839755A1 (fr) 2011-06-17 2012-12-20 President And Fellows Of Harvard College Frizzled 2 en tant que cible pour des anticorps therapeutiques dans le traitement du cancer
ES2769786T3 (es) 2011-10-14 2020-06-29 Recordati Ag Anticuerpos y métodos para enfermedades relacionadas con la vía Wnt
EP3693476B1 (fr) 2012-02-28 2023-10-18 Novartis AG Sélection de patients atteints d'un cancer pour l'administration d'inhibiteurs de la voie de signalisation de wnt au moyen de l'état mutationnel de rnf43
US9713612B2 (en) 2013-03-12 2017-07-25 Curegenix, Inc. Compounds for treatment of cancer
WO2015145388A2 (fr) * 2014-03-27 2015-10-01 Novartis Ag Procédés de traitement de cancers colorectaux avec mutations en amont de la voie wnt
KR20170010764A (ko) * 2014-04-21 2017-02-01 애브비 스템센트알엑스 엘엘씨 신규한 항-rnf43 항체 및 사용 방법
LT3204378T (lt) * 2014-10-08 2019-10-25 Redx Pharma Plc N-piridinilo acetamido dariniai kaip wnt signalinio kelio inhibitoriai
US20160312207A1 (en) * 2015-04-21 2016-10-27 The Board Of Trustees Of The Leland Stanford Junior University R-spondin antagonists and methods of treating cancer associated with aberrant activation of wnt signaling
CA2985813A1 (fr) * 2015-05-26 2016-12-01 Curegenix Corporation Biomarqueurs tumoraux et leur utilisation
US11993645B2 (en) 2017-01-11 2024-05-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions comprising R-Spondin (RSPO) surrogate molecules
US11958891B2 (en) 2017-01-26 2024-04-16 Surrozen Operating, Inc. Tissue-specific Wnt signal enhancing molecules and uses thereof
WO2019245460A1 (fr) * 2018-06-21 2019-12-26 National University Of Singapore Stratification de patients cancéreux hébergeant des mutations oncogènes dans l'ubiquitine ligase e3 rnf43
JP2021530223A (ja) 2018-07-09 2021-11-11 スロゼン, インコーポレイテッド 組織特異性Wntシグナル増強分子及びその使用
US20210299233A1 (en) * 2018-07-12 2021-09-30 The Children's Medical Center Corporation Method for treating cancer
CA3141632A1 (fr) * 2019-06-21 2020-12-24 Regeneron Pharmaceuticals, Inc. Traitement de densite minerale osseuse reduite avec des inhibiteurs de zinc et doigt ring 3 (znrf3)
CN113564249B (zh) * 2020-04-28 2023-06-16 中国科学院分子细胞科学卓越创新中心 CXorf67在判断肿瘤对DNA损伤药物的敏感性中的应用
WO2022104280A1 (fr) 2020-11-16 2022-05-19 Surrozen Operating, Inc. Molécules d'amélioration de signaux wnt spécifiques du fois et leurs utilisations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2431929T3 (es) 2001-09-18 2013-11-28 Genentech, Inc. Composiciones y procedimientos para el diagnóstico y el tratamiento de tumores
CN101613406A (zh) * 2002-06-06 2009-12-30 肿瘤疗法科学股份有限公司 与人结肠癌相关的基因和多肽
ATE500326T1 (de) * 2002-06-06 2011-03-15 Oncotherapy Science Inc Gene und proteine mit bezug zu menschlichem kolonkrebs
US20040247593A1 (en) * 2002-10-04 2004-12-09 Regents Of The University Of California, Methods for treating cancer by inhibiting Wnt signaling
US7718364B2 (en) 2003-03-25 2010-05-18 John Wayne Cancer Institute DNA markers for management of cancer
EP1771207A4 (fr) * 2004-07-09 2009-05-27 Univ California Méthodes destinées à traiter le cancer au moyen d'agents inhibant la signalisation de wnt16
JP2008519829A (ja) * 2004-11-10 2008-06-12 ヒュブレヒト ラボラトリウム Notch経路活性化の阻害による腸腺腫および/または腺癌の処置
CA2601157A1 (fr) 2005-03-16 2006-09-28 Osi Pharmaceuticals, Inc. Biomarqueurs predictifs de reponse anticancereuse a des inhibiteurs de kinase de recepteur de facteur de croissance epidermique
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
WO2011004379A1 (fr) * 2009-07-10 2011-01-13 Tel Hashomer Medical Research Infrastructure And Services Ltd. Compositions et méthodes de traitement du cancer
EP2549399A1 (fr) 2011-07-19 2013-01-23 Koninklijke Philips Electronics N.V. Evaluation d'activité de voie Wnt utilisant un modelage probabilistique d'expression de gène cible
ES2769786T3 (es) 2011-10-14 2020-06-29 Recordati Ag Anticuerpos y métodos para enfermedades relacionadas con la vía Wnt
EP3693476B1 (fr) 2012-02-28 2023-10-18 Novartis AG Sélection de patients atteints d'un cancer pour l'administration d'inhibiteurs de la voie de signalisation de wnt au moyen de l'état mutationnel de rnf43
RS60823B1 (sr) 2015-12-04 2020-10-30 Boehringer Ingelheim Int Biparatopski polipeptidi koji antagonizuju wnt signalizaciju u tumorskim ćelijama

Also Published As

Publication number Publication date
JP2018172408A (ja) 2018-11-08
KR20140132712A (ko) 2014-11-18
BR112014020233A2 (pt) 2017-07-04
PH12014501930A1 (en) 2014-11-24
AU2013226323A1 (en) 2014-09-11
ES2797533T3 (es) 2020-12-02
IL233920A0 (en) 2014-09-30
MX2014010265A (es) 2015-06-23
CL2014002269A1 (es) 2014-12-19
ES2968742T3 (es) 2024-05-13
WO2013130364A1 (fr) 2013-09-06
EP2820151B1 (fr) 2020-03-25
SG11201404492VA (en) 2014-10-30
CN104302782A (zh) 2015-01-21
JP6397335B2 (ja) 2018-09-26
US20150125857A1 (en) 2015-05-07
AU2013226323B2 (en) 2016-07-14
NZ627864A (en) 2015-12-24
EP3693476A1 (fr) 2020-08-12
CA2864306A1 (fr) 2013-09-06
RU2014139044A (ru) 2016-04-20
RU2636000C2 (ru) 2017-11-17
EP3693476B1 (fr) 2023-10-18
US20190203301A1 (en) 2019-07-04
HK1199744A1 (en) 2015-07-17
JP2015511484A (ja) 2015-04-20
EP2820151A1 (fr) 2015-01-07
ZA201405553B (en) 2015-12-23
RU2017120287A (ru) 2018-11-15
US20170306409A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
PH12014501930A1 (en) Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status
Hales et al. New insights into Notch1 regulation of the PI3K–AKT–mTOR1 signaling axis: Targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia
AU2018256477A1 (en) Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
EA201500334A1 (ru) Fgfr3 гибридный ген и лекарственный препарат, нацеленный на него
MX2022000085A (es) Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad.
NZ736853A (en) Methods of treating cancer patients with farnesyl transferase inhibitors
MX2017014381A (es) Metodos terapeuticos y diagnosticos para cancer.
TN2014000063A1 (en) Kinase inhibitor polymorphs
BR112014023162A8 (pt) compostos e métodos para modulação quinase e indicações dos mesmos
MX2014001246A (es) Identificación del perfil de la expresión génica como biomarcador predictivo del estatus de lkb1.
MX2014005800A (es) Mutaciones del receptor notch humano y su uso.
HK1208470A1 (en) Biomarkers for use in integrin therapy applications
EP3284481A4 (fr) Agent induisant la mort cellulaire pour des cellules ayant une mutation du gène braf, agent pour inhiber la prolifération desdites cellules et composition pharmaceutique pour le traitement d'un patient souffrant des effets de la prolifération anormale desdites cellules
WO2015150472A3 (fr) Nouvelles stratégies de traitement du mélanome
MX2017002364A (es) Terapia de combinacion para tratamiento de cancer.
MX2014014097A (es) Biomarcadores para determinar la respuesta eficaz de tratamientos en pacientes de carcinoma hepatocelular (chc).
MX2021000133A (es) Uso de compuestos conocidos como inhibidores de la d-aminoacido oxidasa.
IN2014MN01944A (fr)
GB2523211A8 (en) MCT protein inhibitor-related prognostic and therapeutic methods
MX2016004212A (es) Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas.
WO2012109233A3 (fr) Procédés de prédiction du risque de récidive chez des patients atteints d'un cancer du sein
HRP20180130T1 (hr) Protutumorsko sredstvo i postupak predviđanja terapijskog učinka za pacijente s kolorektalnim rakom s mutacijom kras
WO2013103836A3 (fr) Procédés de traitement du cancer
TH158534A (th) การเลือกผู้ป่วยมะเร็งสำหรับการดำเนินการให้ของตัวยับยั้งการส่งสัญญาณ wnt โดยการใช้ภาวะการกลายพันธุ์ rnf43
PT3284481T (pt) Agente indutor da morte celular para células com mutação do gene braf, agente para inibição da proliferação das referidas células e composição farmacêutica para tratamento de pacientes que sofrem os efeitos da proliferação anormal das referidas células